Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma.
Michael S. Gordon
Research Funding - MedImmune
Jose Lutzky
Research Funding - MedImmune
Donald P. Lawrence
Research Funding - MedImmune
Keith W. Orford
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Andy Blake-Haskins
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Alessandra Di Pietro
Employment or Leadership Position - MedImmune
Paul B. Robbins
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Mohammed M. Dar
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Antoni Ribas
Consultant or Advisory Role - Amgen; Genentech; GlaxoSmithKline; Merck
Stock Ownership - Kite Pharma